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ABSTRACT 
Background and Aims: In patients with hepatocellular carcinoma (HCC), liver 
transplantation (LT) is an excellent therapy if tumor characteristics are within the Milan 
criteria. We aimed to define genomic features enabling to identify HCC patients 
beyond Milan criteria who have acceptable transplant outcomes.  
Methods: Among 770 consecutive HCC patients transplanted between 1990 and 
2013, 132 had tumors exceeding Milan criteria on pathology and were enrolled in the 
study; 44% of the patients satisfied the „up-to-7 rule‟ [7=sum of the size of the largest 
tumor and the number of tumors]. Explant tumors were assessed for genomic 
signatures and immunohistochemical markers associated with poor outcome.  
Results: At a median follow-up of 88 months, 64 patients had died and 45 recurred; 
the 5-year overall survival (OS) and recurrence rates were 57% and 35%, 
respectively. Cytokeratin 19 (CK19) gene signature was independently associated with 
recurrence [Hazard ratio (HR)=2.95, p<0.001], along with tumor size (HR=3.37, 
p=0.023) and presence of satellites (HR=2.98, p=0.001). S2 subclass signature was 
independently associated with poor OS (HR=3.18, p=0.001), along with tumor size 
(HR=5.06, p<0.001) and up-to-7 rule (HR=2.50, p=0.002). Using the presence of 
progenitor cells markers (either CK19 or S2 signatures) patients were classified into 
poor-prognosis (n=58; 5-year recurrence 53%, survival 45%) and good-prognosis 
(n=74; 5-year recurrence 19%, survival 67%) (HR=3.16, p<0.001 for recurrence, and 
HR=1.72, p=0.04 for OS).   
Conclusions:  
HCC patients transplanted beyond Milan criteria without gene signatures of progenitor 
markers (CK19 and S2) achieved survival rates similar as those within Milan criteria. 
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Once prospectively validated, these markers may support a limited expansion of LT 
indications.  
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INTRODUCTION 
Liver transplantation (LT) is an effective treatment option for hepatocellular carcinoma 
(HCC) when disease is defined by the widely accepted Milan criteria [1, 2]. 
Transplantation for patients within the Milan criteria generally yields a 5-year overall 
survival (OS) of 70% and a recurrence rate less than 15% [1-3]. Several efforts have 
been made to expand the criteria based on tumor size and number [4-8]. Although 
downstaging of tumors beyond Milan criteria is accepted by some UNOS regions, it 
has not yet been adopted by international consensus guidelines of LT [9] or guidelines 
of management of HCC [2]. Mazzaferro et al. proposed the up-to-7 rule [the sum of the 
number of tumor nodule(s) and the maximum diameter of the nodule(s) must not 
exceed the value of 7] which, in the absence of microvascular invasion (miVI) results 
in 5-year OS above 70% [8]. This study along with previously published data 
confirmed miVI to be a key predictor of recurrence in patients with HCC [10]. However, 
this information cannot be used in pre-transplant decision-making as an indication of 
transplantation since miVI is only diagnosed based on post-surgical histological 
assessment. This highlights the limitations of the current image-based prognostic 
algorithm for selecting HCC patients for LT.  
 
Genome-wide transcriptome profiling has identified several key deregulated genes, 
molecular pathways and signatures associated with disease progression and 
prognosis in HCC [11, 12]. Activation of specific molecular pathways such as 
transforming growth factor-beta (TGFb) as well as presence of progenitor cell markers 
such as cytokeratin 19 (CK19) and epithelial cell adhesion molecule (EPCAM) have 
been associated with more aggressive biological tumor characteristics and rapid 
disease spread [13-35]. 
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In a previous study, we identified gene signatures that significantly improved prediction 
of HCC recurrence after surgical resection [21]. Here we sought to define if gene 
signatures are also able to identify patients with HCC beyond Milan criteria who 
nevertheless may have acceptable outcomes with LT. In addition, we are providing the 
transcriptomic landscape of patients at more advanced states of the disease 
compared with those undergoing resection or transplantation according to Milan 
criteria, as per AASLD/EASL guidelines [2, 36]. 
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MATERIALS AND METHODS 
Patient cohorts and tissue samples 
A total of 770 patients were transplanted for HCC between 1990 and 2013 at Mount 
Sinai Hospital, New York (n=590) and Mayo Clinic, Scottsdale-Arizona (n=180). 
Among these, we selected 132 patients (Mount Sinai: n=94, Mayo: n=38) with HCC 
beyond Milan criteria by pathological assessment, for whom base-line and follow-up 
clinical information and archived fixed tissue of viable tumor were available (Figure 1). 
The study protocol was approved by the respective Institutional Review Boards. See 
Supplementary Methods. 
 
Genome-wide transcriptome profiling 
Total RNA was subjected to transcriptome profiling using Whole-Genome DASL-HT 
(Illumina). See Supplementary Methods. GEO accession number: GSE62743.  
 
Immunohistochemistry 
Immunohistochemistry was performed for the evaluation of nuclear β-catenin as a 
surrogate for Wnt pathway activation; phosphorylation of ribosomal protein S6 (RPS6) 
as the major downstream effector of activated AKT-mTOR pathway; CK19 and 
EPCAM as surrogate of progenitor cell origin. See Supplementary Methods. 
 
Bioinformatics and statistical analysis 
Presence of previously reported HCC gene signatures (Supplementary Table 1) was 
evaluated (Figure 2). See Supplementary Methods. 
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RESULTS 
Patient characteristics 
Clinico-pathological data and outcomes of the patients are summarized in Table 1. 
Most of the patients were male (80%) and hepatitis C virus (HCV)-infected (71%). The 
median size of the largest tumor was 4 cm (range 1-9 cm). Tumors exceeded Milan 
criteria due to single tumor larger than 5 cm (5%), 2 to 3 tumors with the largest tumor 
larger than 3 cm (39%), or more than 3 tumors within the liver (57%). Satellite lesions 
(defined as HCC nodules < 2 cm in diameter within 2 cm from main tumor [37]) were 
present in 18% and miVI was present in 84% of the patients. Serum alpha fetoprotein 
(AFP) was > 200 mg/dL in 17% of cases. At the end of follow-up, 64 patients had died, 
OS at 5- and 10-years was 57% and 42%, respectively. HCC recurrence developed in 
45 patients, 5 and 10-year cumulative recurrence rates were 35% and 44%, 
respectively (Figure 3).  
Clinical variables identified as predictors of recurrence on multivariate analysis 
included tumor diameter >5 cm [p=0.023, Hazard Ratio (HR) = 3.37] and the presence 
of satellites (p<0.001, HR=2.98). Tumor diameter >5 cm (p<0.001, HR=5.06) and 
outside up-to-7 rule (HR=2.50, p=0.002) predicted poor survival (Tables 2 and 3). 
 
Prevalence of prognostic liver cancer gene signatures 
Among the 22 liver cancer gene signatures tested, 16 were able to sort patients into 
good and poor prognosis groups with a FDR<0.05 (Figure 2A). The human [21] and 
rat [28] CK19 gene signatures were present in 40% and 42% of patients, respectively. 
Signatures associated with poor clinical outcome and/or more aggressive biological 
features were generally present in the same set of tumors. At least one poor-prognosis 
signature was present in 84 patients (64%), this being a higher rate than we have 
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previously reported in patients treated with resection [21]. Twenty-five tumors (19%) 
harbored more than 10 poor prognosis/aggressiveness gene signatures. VI signature 
was positive in 22% of cases, 93% of which were positive for histological miVI. The 
majority of tumors lacking poor prognosis/aggressive signatures were enriched by the 
S3 subclass signature (39/48, 81%), which is associated with smaller, higher 
proportion of well-differentiated tumors [13].  
The gene signatures analyzed were consistent with 3 distinct clusters or major 
molecular classes of HCC (Figure 2B): (1) Proliferation and cell cycle activation 
(Cluster A [16], Cholangiocarcinoma [29], Proliferation [20], Recurrence [24], S1 [13], 
TGFb [23], MET [18], and G3 [19] signatures), 2) Proliferation-progenitor cell origin 
(Hepatoblastoma C2 [26], Class S2 [13], EpCAM [25] and VI [22] signatures), which 
includes a subclass of CK19 positive tumors (CK19 human [21] and rat [28] 
signatures), and 3) non-proliferative class, enriched by tumors positive for 
CTNNB1[20] or class S3 [13, 33]. Interestingly, there was no association between the 
underlying etiology [HCV, Hepatitis B Virus (HBV) or alcohol] and the expression of 
signatures. 
Comparing the classification of signatures between this cohort and previously 
published results from resection cases [21], we noticed a higher frequency of tumors 
positive for > 6 signatures of poor prognosis (32.6% vs 25%, respectively). Similarly, 
our cohort presented a higher prevalence of CK19 human signatures (41% vs 34%, 
respectively), suggesting that it includes more advanced tumors compared with our 
previous report on resected patients [21]. 
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Immunohistochemical (IHC) analysis 
CK19 immunostaining was positive in 6 tumors (5%), and was significantly associated 
with the presence of the human (p=0.03) and rat (p=0.04) CK19 gene signatures, as 
well as VI signature [22] (p<0.01) (Supplementary Table 2). EPCAM immunostaining 
was positive in 20 tumors (15%), and was significantly associated with EPCAM 
signature (p=0.01), human and rat CK19 signatures (p=0.01 and p=0.02, respectively), 
Proliferation subclass signature (p=0.01), and VI signature (p=0.01) (Supplementary 
Table 2). Nuclear staining of β-catenin was observed in 27 tumors (21%), and was 
positively associated with CTNNB1 class signature (p=0.01) (Supplementary Figure 
1, Supplementary Table 2). In addition, 12 samples (9%) had overexpression of 
cytoplasmic β catenin with one third of these in CTNNB1 class (4/12, 33%). Phospho-
RPS6 staining was positive in 75 tumors (57%) with no obvious correlation with any of 
the evaluated gene signatures. 
 
Prognostic relevance of liver cancer gene signatures in LT treated patients 
beyond Milan 
Prognostic gene signatures in HCC were initially developed in patients undergoing 
resection, a treatment indicated for early stages of the disease. Univariate Cox 
regression analysis demonstrated that VI [22], G3 subclass [19], and S2 subclass [13] 
signatures were associated with overall survival, along with patient‟s age, tumor size, 
and up-to-7 rule (Table 2). In the multivariate analysis only S2 signature [13] 
(HR=3.18, p=0.001), tumor diameter >5 cm (HR=5.06, p<0.001), and outside up-to-7 
rule (HR=2.50, p=0.002) were independent predictors of survival. VI [22], G3 [19], 
Proliferation [20], CK19 human [21], CK19 rat [28], Cholangiocarcinoma [29], Cluster 
A [16] and S3 [13] gene signatures were associated with HCC recurrence in univariate 
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analysis along with tumor size, AFP and satellites from clinical variables as well as 
RPS6 from IHC (Table 3). In multivariate analysis, CK19 human [21] (HR=2.91, 
p=0.001), tumor diameter > 5 cm (HR=3.37, p=0.023) and satellites (HR=2.98, 
p<0.001) were independent predictors of recurrence. 
Of note, histological miVI predicted neither survival nor recurrence, presumably 
because in this cohort it was present in the large majority of cases (112 patients, 
84.8%). Also, IHC positivity for reported progenitor cell markers also failed to improve 
outcome prediction. 
 
Combination of progenitor cell signatures (CK19 and S2) discriminates 
prognostic subgroups in transplant patients 
Multivariate analyses demonstrated prognostic significance of two progenitor-related 
gene signatures, CK19 [21] and S2 [13]. Furthermore, S2 subclass signature was also 
able to predict significant shorter survival post-recurrence in a subgroup analysis, 
suggesting that this signature might be able to capture more aggressive tumors with 
high risk of recurrence (p<0.001, HR= 5.11, Supplementary Figure 2). We therefore 
explored whether combining these signatures could further improve our ability to 
predict outcome. At least one of these two signatures was present in 58 patients 
(44%), and having one or both signatures independently predicted both OS (HR=1.72, 
p=0.036) and recurrence (HR=3.16, p=0.001) (Tables 4 and 5): patients with one or 
both signatures had 45% 5-year OS and 53% recurrence vs 67% 5-year OS and 19% 
recurrence when neither signature was present (Figure 3C-D). The presence of any of 
the two signatures also predicted recurrence when the analysis was limited to patients 
beyond Milan criteria based on preoperative imaging (n=94) (Supplementary Figure 
3, Supplementary Table 3).  Overall, 5-year recurrence rate was of 35.7% and was 
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significantly lower in patients CK19/S2 rule negative  (20.8% vs 52.8%, p=0.003). 
Furthermore, the CK19/S2 rule, when applied to patients classified according to BCLC 
stage, significantly improved the prognostic prediction by stratifying patients in high 
and low risk for both recurrence and survival (Supplementary Figures 4 and 5). 
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Discussion 
Almost 20 years after the seminal observation by Mazzaferro et al [1], we 
continue to rely on size and number of tumors for selecting patients with HCC for LT. 
Since then, the concept of a modest expansion beyond the Milan criteria has been 
proposed without gaining global acceptance [4, 38-39]. Most of the studies performed 
were retrospective, used pathological data and only included few patients with HCC 
beyond Milan criteria, thus leading to unrealistic good results because the outcome 
was “diluted” among a much larger pool of patients within Milan criteria. The largest 
series ever reported exploring expansion of Milan criteria led to the pathological up-to-
7 rule where outcomes were significantly better for patients within this rule, as long as 
vascular invasion is not present [8]. After all, tumor size and number remain 
surrogates for the biological aggressiveness of HCC; henceforth more refined markers 
are needed. 
While there have been multiple publications linking various genetic profiles of 
HCC with outcomes after hepatic resection, tumor biology in transplanted patients has 
not been assessed widely thus far. Most studies have relied on degree of HCC 
differentiation on biopsy, AFP and response to bridge therapy while on the waiting list 
[40-42]. Using allelic imbalance, we described that genomic instability of certain 
microsatellites selected for proximity to known oncogenes can help select patients 
beyond Milan criteria who are likely to have favorable outcomes after transplantation 
[43]. Because gene expression profiling could be eventually performed on needle liver 
biopsies in a pre-transplant setting [44], the positivity for each of the signatures can 
assist in the decision making of selecting patients for transplantation. 
In our current study, we explored the tumor gene expression profiles for the 
presence of 22 previously reported prognostic signatures –reflecting HCC molecular 
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subclasses or activation of signaling pathways- in 132 patients transplanted with HCC 
beyond Milan criteria and key immunohistochemical staining and correlated the results 
with clinical variables and outcome. Sixteen signatures demonstrated association with 
recurrence and/or survival; among these the CK19 and the S2 signatures, both 
denoting progenitor cell features, were independent predictors of outcome when 
included in models incorporating clinical variables. As shown in Figure 2, both 
signatures cluster together along with others from hepatoblastoma, which overall 
reflect progenitor cell origin. In fact, CK19 is a molecular marker of progenitor cells, 
whereas S2 subclass [13] has been linked with high levels of expression of AFP even 
at early stages of the disease, and activation of mTOR and IGF signaling [21, 35]. We 
also found enrichment for Met and TGFb signaling in these patients. In our study, one 
and/or both signatures were present in 44% of cases and the overall 5 yr-survival and 
recurrence rate (53% and 45%, respectively) was discouraging. Conversely, in the 
56% of patients harboring neither signature, OS was 67% and recurrence was 19% at 
5 years, similar to the results of LT for HCC when conventional Milan criteria are 
applied. The capacity of our tool to rule out tumors with “poor biology” is directly 
reflected in the acceptable low recurrence rate.  
In order to be used prospectively, the CK19/S2 gene signature needs to be 
validated when Milan criteria are defined on pre-operative imaging. Indeed, in the 
subgroup analysis of pre-operatively defined cases beyond Milan criteria, the CK19/S2 
signature remained independently associated with recurrence. However, the signature 
no longer retained significance on multivariate analysis for overall survival, likely due 
to the smaller sample size. Overall, these findings support the possibility that genomic 
analysis of HCC performed prior to LT may enable expansion of the current imaging-
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based selection criteria to include patients beyond Milan Criteria but with favorable 
genomic profiles, without significantly impacting clinical outcome. 
Another interesting finding of our study was the relative genomic disparity observed in 
HCC cases treated with LT versus those undergoing resection. In this series of 
patients with HCC beyond Milan Criteria we observed a higher frequency of tumors 
demonstrating ≥ 6 signatures than we did in the study of patients undergoing liver 
resection [21].This may be explained, to some degree, by the more advanced clinical 
stage of cancers that received LT beyond Milan criteria versus those undergoing 
resection. While resection is limited to single tumors, nearly 95% of the patients in the 
current study were transplanted for multiple HCC. 
We intend to validate these observations prospectively, but in order to establish 
the absence of the CK19 and S2 progenitor cell signatures as a basis for safe 
expansion of the indication for LT for patients with HCC, a number of barriers must be 
overcome. First, the study will have to be limited to patients identified pre-LT as being 
beyond Milan Criteria in order to be clinically relevant. The genomic heterogeneity of 
tumors is widely recognized, all the more so when the tumor is large or multinodular as 
in patients beyond Milan Criteria. While we have shown in a limited study that genomic 
heterogeneity in HCC rarely results in assignment of samples from the same tumor to 
different genomic classes [21], the degree to which a pre-LT biopsy accurately reflects 
the genomic landscape of the tumor remains unclear. Molecular heterogeneity 
between and within tumors can pose a risk for miss-classifications when selecting the 
area to biopsy prior LT. However, with the advancements of imaging techniques, a 
significant correlation has been shown between tumor enhancement and histological 
differentiation which could greatly assist in more accurate profiling [45].  
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On the other side, the impact on gene expression of pre-LT nonsurgical tumor 
treatment, that is commonly performed to down-stage HCC and forestalls progression 
while awaiting transplant, remains undefined. Furthermore, with long pre-LT waiting 
times before transplantation and the potential drop out of some patients, the stability of 
tumor gene expression profiles over time must be considered. Thus, the extent to 
which a biopsy done today reflects the nature of the tumor later on and the frequency 
with which biopsy will need to be repeated, need to be determined. 
Despite its shortcomings, our observations provide initial insights into the 
understanding of tumor biology and clinical outcomes beyond size and number of 
HCC nodules. Those patients with tumors with “good biology” as defined by absence 
of signatures with progenitor cell traits (CK19/S2) represent half of the patients 
transplanted beyond Milan criteria in 2 institutions in the United States. Our seminal 
study provides the rationale for expanding the conventional criteria based upon 
genomic data, since outcomes are competitive with those achieved by HCC patients 
within Milan criteria. It is a novel, genomic, complementary tool to refine previously 
reported proposals, such as Up-to-7 rule [8]. Certainly, these results need to be 
validated using a separate external cohort of patients and then examined 
prospectively before they can be adopted by clinical guidelines. 
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FIGURE LEGENDS 
Figure 1: Flow chart of the study. The initial cohort included 770 patients that were 
consecutively transplanted for HCC at Mount Sinai Hospital, New York (n=590) and 
Mayo Clinic, Scottdale Arizona (n=180). A total of 206 patients were beyond Milan 
criteria based on the explant pathology. Tumors with HCC-ICC features, diffused 
pattern, necrotic tissue, macro-vascular invasion or metastasis were excluded. From 
the remaining 141 cases, 6 tumors with poor-quality RNA were discarded. Total RNA 
from 135 tumors was subjected to transcriptome profiling. Three samples had poor 
quality profile and were excluded and eventually 132 tumors were tested for the 
presence of previously reported outcome-associated gene signatures.  
 
Figure 2: Prediction of gene expression signatures. Only signatures that were able 
to assign patients into good and poor prognosis groups with FDR>0.05 were included. 
(A) Each column represents different sample and each row different signature. 
Positivity of each signature is represented by red bars. Events (recurrence or 5-year 
death) are shown with black bars. (B) Visualization of cramer‟s V coefficient for the 
pair-wise comparison of gene signatures. The scale from blue to red represents the 
strength of correlation (red represents the highest correlation). The signatures are 
clustered according to their correlation. 
 
Figure 3: Kaplan-Meier curves and estimates of overall survival and recurrence 
in patients beyond Milan undergoing liver transplantation (n=132). Top figures 
show overall survival and recurrence in this cohort. Patients positive for either of CK19 
or S2 signatures (progenitor-cell signatures) were assigned in a poor-outcome group. 
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Lower panels show overall survival and recurrence in patients beyond Milan with or 
without CK19/S2 signatures. P-values are calculated based on the log-rank test. 
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AFP: Alpha-fetoprotein 
IHC, immunohistochemical 
RPS6: ribosomal protein S6 
FDR: False discovery rate  
H&E: Hematoxylin and eosin 
PPV: Positive predictive value 
NPV: Negative predictive value 
HCV: Hepatitis C virus   
HBV: Hepatitis B Virus  
VIF: Variance Inflation Factor 
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ABSTRACT 
Background and Aims: In patients with hepatocellular carcinoma (HCC), liver 
transplantation (LT) is an excellent therapy if tumor characteristics are within the Milan 
criteria. We aimed to define genomic features enabling to identify HCC patients 
beyond Milan criteria who have acceptable transplant outcomes.  
Methods: Among 770 consecutive HCC patients transplanted between 1990 and 
2013, 132 had tumors exceeding Milan criteria on pathology and were enrolled in the 
study; 44% of the patients satisfied the „up-to-7 rule‟ [7=sum of the size of the largest 
tumor and the number of tumors]. Explant tumors were assessed for genomic 
signatures and immunohistochemical markers associated with poor outcome.  
Results: At a median follow-up of 88 months, 64 patients had died and 45 recurred; 
the 5-year overall survival (OS) and recurrence rates were 57% and 35%, 
respectively. Cytokeratin 19 (CK19) gene signature was independently associated with 
recurrence [Hazard ratio (HR)=2.95, p<0.001], along with tumor size (HR=3.37, 
p=0.023) and presence of satellites (HR=2.98, p=0.001). S2 subclass signature was 
independently associated with poor OS (HR=3.18, p=0.001), along with tumor size 
(HR=5.06, p<0.001) and up-to-7 rule (HR=2.50, p=0.002). Using the presence of 
progenitor cells markers (either CK19 or S2 signatures) patients were classified into 
poor-prognosis (n=58; 5-year recurrence 53%, survival 45%) and good-prognosis 
(n=74; 5-year recurrence 19%, survival 67%) (HR=3.16, p<0.001 for recurrence, and 
HR=1.72, p=0.04 for OS).   
Conclusions:  
HCC patients transplanted beyond Milan criteria without gene signatures of progenitor 
markers (CK19 and S2) achieved survival rates similar as those within Milan criteria. 
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Once prospectively validated, these markers may support a limited expansion of LT 
indications.  
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INTRODUCTION 
Liver transplantation (LT) is an effective treatment option for hepatocellular carcinoma 
(HCC) when disease is defined by the widely accepted Milan criteria [1, 2]. 
Transplantation for patients within the Milan criteria generally yields a 5-year overall 
survival (OS) of 70% and a recurrence rate less than 15% [1-3]. Several efforts have 
been made to expand the criteria based on tumor size and number [4-8]. Although 
downstaging of tumors beyond Milan criteria is accepted by some UNOS regions, it 
has not yet been adopted by international consensus guidelines of LT [9] or guidelines 
of management of HCC [2]. Mazzaferro et al. proposed the up-to-7 rule [the sum of the 
number of tumor nodule(s) and the maximum diameter of the nodule(s) must not 
exceed the value of 7] which, in the absence of microvascular invasion (miVI) results 
in 5-year OS above 70% [8]. This study along with previously published data 
confirmed miVI to be a key predictor of recurrence in patients with HCC [10]. However, 
this information cannot be used in pre-transplant decision-making as an indication of 
transplantation since miVI is only diagnosed based on post-surgical histological 
assessment. This highlights the limitations of the current image-based prognostic 
algorithm for selecting HCC patients for LT.  
 
Genome-wide transcriptome profiling has identified several key deregulated genes, 
molecular pathways and signatures associated with disease progression and 
prognosis in HCC [11, 12]. Activation of specific molecular pathways such as 
transforming growth factor-beta (TGFb) as well as presence of progenitor cell markers 
such as cytokeratin 19 (CK19) and epithelial cell adhesion molecule (EPCAM) have 
been associated with more aggressive biological tumor characteristics and rapid 
disease spread [13-35]. 
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In a previous study, we identified gene signatures that significantly improved prediction 
of HCC recurrence after surgical resection [21]. Here we sought to define if gene 
signatures are also able to identify patients with HCC beyond Milan criteria who 
nevertheless may have acceptable outcomes with LT. In addition, we are providing the 
transcriptomic landscape of patients at more advanced states of the disease 
compared with those undergoing resection or transplantation according to Milan 
criteria, as per AASLD/EASL guidelines [2, 36]. 
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MATERIALS AND METHODS 
Patient cohorts and tissue samples 
A total of 770 patients were transplanted for HCC between 1990 and 2013 at Mount 
Sinai Hospital, New York (n=590) and Mayo Clinic, Scottsdale-Arizona (n=180). 
Among these, we selected 132 patients (Mount Sinai: n=94, Mayo: n=38) with HCC 
beyond Milan criteria by pathological assessment, for whom base-line and follow-up 
clinical information and archived fixed tissue of viable tumor were available (Figure 1). 
The study protocol was approved by the respective Institutional Review Boards. See 
Supplementary Methods. 
 
Genome-wide transcriptome profiling 
Total RNA was subjected to transcriptome profiling using Whole-Genome DASL-HT 
(Illumina). See Supplementary Methods. GEO accession number: GSE62743.  
 
Immunohistochemistry 
Immunohistochemistry was performed for the evaluation of nuclear β-catenin as a 
surrogate for Wnt pathway activation; phosphorylation of ribosomal protein S6 (RPS6) 
as the major downstream effector of activated AKT-mTOR pathway; CK19 and 
EPCAM as surrogate of progenitor cell origin. See Supplementary Methods. 
 
Bioinformatics and statistical analysis 
Presence of previously reported HCC gene signatures (Supplementary Table 1) was 
evaluated (Figure 2). See Supplementary Methods. 
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RESULTS 
Patient characteristics 
Clinico-pathological data and outcomes of the patients are summarized in Table 1. 
Most of the patients were male (80%) and hepatitis C virus (HCV)-infected (71%). The 
median size of the largest tumor was 4 cm (range 1-9 cm). Tumors exceeded Milan 
criteria due to single tumor larger than 5 cm (5%), 2 to 3 tumors with the largest tumor 
larger than 3 cm (39%), or more than 3 tumors within the liver (57%). Satellite lesions 
(defined as HCC nodules < 2 cm in diameter within 2 cm from main tumor [37]) were 
present in 18% and miVI was present in 84% of the patients. Serum alpha fetoprotein 
(AFP) was > 200 mg/dL in 17% of cases. At the end of follow-up, 64 patients had died, 
OS at 5- and 10-years was 57% and 42%, respectively. HCC recurrence developed in 
45 patients, 5 and 10-year cumulative recurrence rates were 35% and 44%, 
respectively (Figure 3).  
Clinical variables identified as predictors of recurrence on multivariate analysis 
included tumor diameter >5 cm [p=0.023, Hazard Ratio (HR) = 3.37] and the presence 
of satellites (p<0.001, HR=2.98). Tumor diameter >5 cm (p<0.001, HR=5.06) and 
outside up-to-7 rule (HR=2.50, p=0.002) predicted poor survival (Tables 2 and 3). 
 
Prevalence of prognostic liver cancer gene signatures 
Among the 22 liver cancer gene signatures tested, 16 were able to sort patients into 
good and poor prognosis groups with a FDR<0.05 (Figure 2A). The human [21] and 
rat [28] CK19 gene signatures were present in 40% and 42% of patients, respectively. 
Signatures associated with poor clinical outcome and/or more aggressive biological 
features were generally present in the same set of tumors. At least one poor-prognosis 
signature was present in 84 patients (64%), this being a higher rate than we have 
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previously reported in patients treated with resection [21]. Twenty-five tumors (19%) 
harbored more than 10 poor prognosis/aggressiveness gene signatures. VI signature 
was positive in 22% of cases, 93% of which were positive for histological miVI. The 
majority of tumors lacking poor prognosis/aggressive signatures were enriched by the 
S3 subclass signature (39/48, 81%), which is associated with smaller, higher 
proportion of well-differentiated tumors [13].  
The gene signatures analyzed were consistent with 3 distinct clusters or major 
molecular classes of HCC (Figure 2B): (1) Proliferation and cell cycle activation 
(Cluster A [16], Cholangiocarcinoma [29], Proliferation [20], Recurrence [24], S1 [13], 
TGFb [23], MET [18], and G3 [19] signatures), 2) Proliferation-progenitor cell origin 
(Hepatoblastoma C2 [26], Class S2 [13], EpCAM [25] and VI [22] signatures), which 
includes a subclass of CK19 positive tumors (CK19 human [21] and rat [28] 
signatures), and 3) non-proliferative class, enriched by tumors positive for 
CTNNB1[20] or class S3 [13, 33]. Interestingly, there was no association between the 
underlying etiology [HCV, Hepatitis B Virus (HBV) or alcohol] and the expression of 
signatures. 
Comparing the classification of signatures between this cohort and previously 
published results from resection cases [21], we noticed a higher frequency of tumors 
positive for > 6 signatures of poor prognosis (32.6% vs 25%, respectively). Similarly, 
our cohort presented a higher prevalence of CK19 human signatures (41% vs 34%, 
respectively), suggesting that it includes more advanced tumors compared with our 
previous report on resected patients [21]. 
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Immunohistochemical (IHC) analysis 
CK19 immunostaining was positive in 6 tumors (5%), and was significantly associated 
with the presence of the human (p=0.03) and rat (p=0.04) CK19 gene signatures, as 
well as VI signature [22] (p<0.01) (Supplementary Table 2). EPCAM immunostaining 
was positive in 20 tumors (15%), and was significantly associated with EPCAM 
signature (p=0.01), human and rat CK19 signatures (p=0.01 and p=0.02, respectively), 
Proliferation subclass signature (p=0.01), and VI signature (p=0.01) (Supplementary 
Table 2). Nuclear staining of β-catenin was observed in 27 tumors (21%), and was 
positively associated with CTNNB1 class signature (p=0.01) (Supplementary Figure 
1, Supplementary Table 2). In addition, 12 samples (9%) had overexpression of 
cytoplasmic β catenin with one third of these in CTNNB1 class (4/12, 33%). Phospho-
RPS6 staining was positive in 75 tumors (57%) with no obvious correlation with any of 
the evaluated gene signatures. 
 
Prognostic relevance of liver cancer gene signatures in LT treated patients 
beyond Milan 
Prognostic gene signatures in HCC were initially developed in patients undergoing 
resection, a treatment indicated for early stages of the disease. Univariate Cox 
regression analysis demonstrated that VI [22], G3 subclass [19], and S2 subclass [13] 
signatures were associated with overall survival, along with patient‟s age, tumor size, 
and up-to-7 rule (Table 2). In the multivariate analysis only S2 signature [13] 
(HR=3.18, p=0.001), tumor diameter >5 cm (HR=5.06, p<0.001), and outside up-to-7 
rule (HR=2.50, p=0.002) were independent predictors of survival. VI [22], G3 [19], 
Proliferation [20], CK19 human [21], CK19 rat [28], Cholangiocarcinoma [29], Cluster 
A [16] and S3 [13] gene signatures were associated with HCC recurrence in univariate 
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analysis along with tumor size, AFP and satellites from clinical variables as well as 
RPS6 from IHC (Table 3). In multivariate analysis, CK19 human [21] (HR=2.91, 
p=0.001), tumor diameter > 5 cm (HR=3.37, p=0.023) and satellites (HR=2.98, 
p<0.001) were independent predictors of recurrence. 
Of note, histological miVI predicted neither survival nor recurrence, presumably 
because in this cohort it was present in the large majority of cases (112 patients, 
84.8%). Also, IHC positivity for reported progenitor cell markers also failed to improve 
outcome prediction. 
 
Combination of progenitor cell signatures (CK19 and S2) discriminates 
prognostic subgroups in transplant patients 
Multivariate analyses demonstrated prognostic significance of two progenitor-related 
gene signatures, CK19 [21] and S2 [13]. Furthermore, S2 subclass signature was also 
able to predict significant shorter survival post-recurrence in a subgroup analysis, 
suggesting that this signature might be able to capture more aggressive tumors with 
high risk of recurrence (p<0.001, HR= 5.11, Supplementary Figure 2). We therefore 
explored whether combining these signatures could further improve our ability to 
predict outcome. At least one of these two signatures was present in 58 patients 
(44%), and having one or both signatures independently predicted both OS (HR=1.72, 
p=0.036) and recurrence (HR=3.16, p=0.001) (Tables 4 and 5): patients with one or 
both signatures had 45% 5-year OS and 53% recurrence vs 67% 5-year OS and 19% 
recurrence when neither signature was present (Figure 3C-D). The presence of any of 
the two signatures also predicted recurrence when the analysis was limited to patients 
beyond Milan criteria based on preoperative imaging (n=94) (Supplementary Figure 
3, Supplementary Table 3).  Overall, 5-year recurrence rate was of 35.7% and was 
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significantly lower in patients CK19/S2 rule negative  (20.8% vs 52.8%, p=0.003). 
Furthermore, the CK19/S2 rule, when applied to patients classified according to BCLC 
stage, significantly improved the prognostic prediction by stratifying patients in high 
and low risk for both recurrence and survival (Supplementary Figures 4 and 5). 
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Discussion 
Almost 20 years after the seminal observation by Mazzaferro et al [1], we 
continue to rely on size and number of tumors for selecting patients with HCC for LT. 
Since then, the concept of a modest expansion beyond the Milan criteria has been 
proposed without gaining global acceptance [4, 38-39]. Most of the studies performed 
were retrospective, used pathological data and only included few patients with HCC 
beyond Milan criteria, thus leading to unrealistic good results because the outcome 
was “diluted” among a much larger pool of patients within Milan criteria. The largest 
series ever reported exploring expansion of Milan criteria led to the pathological up-to-
7 rule where outcomes were significantly better for patients within this rule, as long as 
vascular invasion is not present [8]. After all, tumor size and number remain 
surrogates for the biological aggressiveness of HCC; henceforth more refined markers 
are needed. 
While there have been multiple publications linking various genetic profiles of 
HCC with outcomes after hepatic resection, tumor biology in transplanted patients has 
not been assessed widely thus far. Most studies have relied on degree of HCC 
differentiation on biopsy, AFP and response to bridge therapy while on the waiting list 
[40-42]. Using allelic imbalance, we described that genomic instability of certain 
microsatellites selected for proximity to known oncogenes can help select patients 
beyond Milan criteria who are likely to have favorable outcomes after transplantation 
[43]. Because gene expression profiling could be eventually performed on needle liver 
biopsies in a pre-transplant setting [44], the positivity for each of the signatures can 
assist in the decision making of selecting patients for transplantation. 
In our current study, we explored the tumor gene expression profiles for the 
presence of 22 previously reported prognostic signatures –reflecting HCC molecular 
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subclasses or activation of signaling pathways- in 132 patients transplanted with HCC 
beyond Milan criteria and key immunohistochemical staining and correlated the results 
with clinical variables and outcome. Sixteen signatures demonstrated association with 
recurrence and/or survival; among these the CK19 and the S2 signatures, both 
denoting progenitor cell features, were independent predictors of outcome when 
included in models incorporating clinical variables. As shown in Figure 2, both 
signatures cluster together along with others from hepatoblastoma, which overall 
reflect progenitor cell origin. In fact, CK19 is a molecular marker of progenitor cells, 
whereas S2 subclass [13] has been linked with high levels of expression of AFP even 
at early stages of the disease, and activation of mTOR and IGF signaling [21, 35]. We 
also found enrichment for Met and TGFb signaling in these patients. In our study, one 
and/or both signatures were present in 44% of cases and the overall 5 yr-survival and 
recurrence rate (53% and 45%, respectively) was discouraging. Conversely, in the 
56% of patients harboring neither signature, OS was 67% and recurrence was 19% at 
5 years, similar to the results of LT for HCC when conventional Milan criteria are 
applied. The capacity of our tool to rule out tumors with “poor biology” is directly 
reflected in the acceptable low recurrence rate.  
In order to be used prospectively, the CK19/S2 gene signature needs to be 
validated when Milan criteria are defined on pre-operative imaging. Indeed, in the 
subgroup analysis of pre-operatively defined cases beyond Milan criteria, the CK19/S2 
signature remained independently associated with recurrence. However, the signature 
no longer retained significance on multivariate analysis for overall survival, likely due 
to the smaller sample size. Overall, these findings support the possibility that genomic 
analysis of HCC performed prior to LT may enable expansion of the current imaging-
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based selection criteria to include patients beyond Milan Criteria but with favorable 
genomic profiles, without significantly impacting clinical outcome. 
Another interesting finding of our study was the relative genomic disparity observed in 
HCC cases treated with LT versus those undergoing resection. In this series of 
patients with HCC beyond Milan Criteria we observed a higher frequency of tumors 
demonstrating ≥ 6 signatures than we did in the study of patients undergoing liver 
resection [21].This may be explained, to some degree, by the more advanced clinical 
stage of cancers that received LT beyond Milan criteria versus those undergoing 
resection. While resection is limited to single tumors, nearly 95% of the patients in the 
current study were transplanted for multiple HCC. 
We intend to validate these observations prospectively, but in order to establish 
the absence of the CK19 and S2 progenitor cell signatures as a basis for safe 
expansion of the indication for LT for patients with HCC, a number of barriers must be 
overcome. First, the study will have to be limited to patients identified pre-LT as being 
beyond Milan Criteria in order to be clinically relevant. The genomic heterogeneity of 
tumors is widely recognized, all the more so when the tumor is large or multinodular as 
in patients beyond Milan Criteria. While we have shown in a limited study that genomic 
heterogeneity in HCC rarely results in assignment of samples from the same tumor to 
different genomic classes [21], the degree to which a pre-LT biopsy accurately reflects 
the genomic landscape of the tumor remains unclear. Molecular heterogeneity 
between and within tumors can pose a risk for miss-classifications when selecting the 
area to biopsy prior LT. However, with the advancements of imaging techniques, a 
significant correlation has been shown between tumor enhancement and histological 
differentiation which could greatly assist in more accurate profiling [45].  
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On the other side, the impact on gene expression of pre-LT nonsurgical tumor 
treatment, that is commonly performed to down-stage HCC and forestalls progression 
while awaiting transplant, remains undefined. Furthermore, with long pre-LT waiting 
times before transplantation and the potential drop out of some patients, the stability of 
tumor gene expression profiles over time must be considered. Thus, the extent to 
which a biopsy done today reflects the nature of the tumor later on and the frequency 
with which biopsy will need to be repeated, need to be determined. 
Despite its shortcomings, our observations provide initial insights into the 
understanding of tumor biology and clinical outcomes beyond size and number of 
HCC nodules. Those patients with tumors with “good biology” as defined by absence 
of signatures with progenitor cell traits (CK19/S2) represent half of the patients 
transplanted beyond Milan criteria in 2 institutions in the United States. Our seminal 
study provides the rationale for expanding the conventional criteria based upon 
genomic data, since outcomes are competitive with those achieved by HCC patients 
within Milan criteria. It is a novel, genomic, complementary tool to refine previously 
reported proposals, such as Up-to-7 rule [8]. Certainly, these results need to be 
validated using a separate external cohort of patients and then examined 
prospectively before they can be adopted by clinical guidelines. 
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FIGURE LEGENDS 
Figure 1: Flow chart of the study. The initial cohort included 770 patients that were 
consecutively transplanted for HCC at Mount Sinai Hospital, New York (n=590) and 
Mayo Clinic, Scottdale Arizona (n=180). A total of 206 patients were beyond Milan 
criteria based on the explant pathology. Tumors with HCC-ICC features, diffused 
pattern, necrotic tissue, macro-vascular invasion or metastasis were excluded. From 
the remaining 141 cases, 6 tumors with poor-quality RNA were discarded. Total RNA 
from 135 tumors was subjected to transcriptome profiling. Three samples had poor 
quality profile and were excluded and eventually 132 tumors were tested for the 
presence of previously reported outcome-associated gene signatures.  
 
Figure 2: Prediction of gene expression signatures. Only signatures that were able 
to assign patients into good and poor prognosis groups with FDR>0.05 were included. 
(A) Each column represents different sample and each row different signature. 
Positivity of each signature is represented by red bars. Events (recurrence or 5-year 
death) are shown with black bars. (B) Visualization of cramer‟s V coefficient for the 
pair-wise comparison of gene signatures. The scale from blue to red represents the 
strength of correlation (red represents the highest correlation). The signatures are 
clustered according to their correlation. 
 
Figure 3: Kaplan-Meier curves and estimates of overall survival and recurrence 
in patients beyond Milan undergoing liver transplantation (n=132). Top figures 
show overall survival and recurrence in this cohort. Patients positive for either of CK19 
or S2 signatures (progenitor-cell signatures) were assigned in a poor-outcome group. 
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Lower panels show overall survival and recurrence in patients beyond Milan with or 
without CK19/S2 signatures. P-values are calculated based on the log-rank test. 
 
 
 
 
1 
 
*BCLC defined with pre-operative clinical and radiological variables. Because patients were treated with liver transplantation, 
Child C patients were not considered BCLC D and were relocated regardless of liver function. 
Table 1: Description of the main clinical and pathological characteristics of HCC patients 
undergoing LT beyond Milan criteria according to center and overall cohort (n=132) 
 
 Overall cohort (n=132) Mount Sinai (n=94) Mayo Clinic (n=38) 
Variable n (%) n (%) n (%) 
n 132 (100) 94 (71.2) 38 (28.8) 
Age>60 39 (29.5) 28 (29.8) 11 (28.9) 
Gender (males) 105 (79.5) 75 (79.8) 30 (78.9) 
Transplant type      
Cadaveric donor 106 (80.3) 77 (81.9) 29 (76.3) 
Living Donor 23 (17.4) 15 (16.0) 8 (21.1) 
Underlying etiology*      
HCV 94 (71.2) 69 (73.4) 25 (65.8) 
HBV 19 (14.4) 17 (18.1) 2 (5.26) 
Alcohol 24 (18.2) 15 (16.0) 9 (23.7) 
Other 10 (7.6) 8 (6.4) 4 (10.5) 
Larger tumor size      
≤3cm 37 (28.0) 27 (28.7) 10 (26.3) 
3-5cm 63 (47.7) 45 (47.9) 18 (47.4) 
≥5cm 32 (24.2) 22 (23.4) 10 (26.3) 
Number of tumors      
1-2 39 (29.5) 25 (26.6) 14 (36.8) 
3-4 40 (30.3) 29 (30.8) 11 (28.9) 
>5 53 (40.2) 40 (42.6) 13 (34.2) 
Reason for extended criteria      
single tumor >5cm tumor 6 (4.5) 4 (4.3) 2 (5.3) 
2-3 tumors, larger  >3cm 51 (38.6) 34 (36.2) 17(44.7) 
>3 tumors 74 (56.1) 55 (58.5) 19 (50) 
Pathological markers      
Well Differentiated 15 (11.4) 8 (8.5) 7 (18.4) 
Moderately Differentiated 52 (39.4) 32 (34.0) 20 (52.6) 
Poorly Differentiated 65 (49.2) 54 (57.4) 11 (28.9) 
Satellites 24 (18.2) 22 (23.4) 2 (5.26) 
Microvascular invasion 112 (84.8) 90 (95.7) 22 (57.9) 
Satisfying up-to-7 rule 56 (44.1) 37 (41.1) 19 (51.4) 
Within Mil  pre-op 33 (26) 11 (12.4) 22 (57.9) 
Alpha-fetoprotein >100mg/dL 30 (22.7) 25 (26.6) 5 (13.2) 
Alpha-fetoprotein >200mg/dL 23 (17.4) 19 (20.2) 4 (10.5) 
Albumin (<3.5mg/dL) 87 (65.9) 68 (72.3) 19(50) 
Bilirubin (>1mg/dL) 100 (75.8) 77 (81.9) 23 (60.5) 
Child Pugh       
Class A 53 (40.2) 29 (36.3) 24 (63.2) 
Class B 36 (30.5) 28 (35.0) 8 (21) 
Class C 29 (24.6) 23 (28.8) 6 (15.8) 
BCLC*       
A 27 (23.9) 23 (29.9) 4 (11.1) 
B 86 (76.1) 54 (70.1) 32 (88.9) 
Events       
Deaths 64 (48.5) 51 (54.3) 13 (34.2) 
Overall Recurrence 45 (34.1) 34 (36.2) 11 (28.9) 
Early Recurrence (<2years) 30 (22.7) 24 (25.5) 6 (15.8) 
Follow up (months) 
median[Q25-Q75] 88 (65-122)        98 (78-138) 66 (37-80) 
5-year Overall survival (%)l 57.0 54.5 64.7 
5-year Recurrence (%) 34.5 35.7 31.7 
        
    
    
Tables
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Table 2: Univariate and Multivariate analysis of clinical, pathological and gene 
signatures for overall survival in patients beyond Milan criteria (n=132) 
  
     
    Overall Survival, events n=64 
   
  
 Patients 
 
Univariate analysis 
 
Multivariate analysis 
Gene expression signatures Pos Rest pval HR 95% CI pval HR 95% CI 
VI signature [22]  29 103 0.040 1.760 1.02-3.04    
G3 signature [19]  40 92 0.040 1.705 1.02-2.86    
Proliferation [20]  39 93 0.250 1.356 0.80-2.29    
CK19  human [21]  53 79 0.054 1.611 0.99-2.63    
CK19 rat [28]  56 76 0.130 1.457 0.89-2.38    
MET signature [18]  34 98 0.458 0.800 0.44-1.45    
Hepatoblastoma_C2 [26]  6 126 0.086 2.369 0.86-6.56    
CTNNB1 [20]  30 102 0.208 1.435 0.81-2.53    
EpCAM 
 
[25]  26 106 0.411 1.281 0.71-2.32    
Cholangiocarcinoma [29]  44 88 0.471 1.209 0.72-2.03    
Recurrence [24]  41 91 0.713 1.104 0.65-1.88    
Cluster A [16]  45 87 0.369 1.264 0.76-2.11    
TGFb [23]  38 94 0.762 0.918 0.53-1.60    
S1 [13]  42 90 0.545 0.845 0.49-1.46    
S2 [13]  15 117 0.011 2.274 1.18-4.37 0.001 3.177 1.60-6.31 
S3 [13]  47 85 0.358 0.781 0.50-1.33    
            
IHC           
CK19   6 126 0.571 1.396 0.44-4.46    
EpCAM   20 112 0.096 0.497 0.21-1.15    
bcatenin   27 105 0.334 1.329 0.74-2.37    
RPS6   75 57 0.173 1.414 0.86-2.33    
            
Clinical Variables           
Male gender   105 27 0.441 0.775 0.40-1.49    
Age (>60)   39 93 0.031 1.730 1.04-2.87    
Etiology  HCV 94 38 0.168 1.512 0.84-2.74    
  HBV 19 113 0.381 0.718 0.34-1.51    
  Alcohol 24 108 0.363 1.316 0.73-2.39    
Single tumor >5cm   6 126 <0.001 4.289 1.83-10.07 <0.001 5.057 2.06-12.44 
2-3 tumors, largest >3cm 51 81 0.118 0.659 0.39-1.12    
No of tumors (>3)   75 57 0.675 1.112 0.68-1.83    
AFP (>200mg/dL)   23 109 0.087 1.650 0.92-2.95    
MiVI   112 20 0.051 2.631 0.96-7.24    
Satellites   24 108 0.056 1.724 0.98-3.04    
Differentiation (Poor)  65 67 0.183 1.398 0.85-2.30    
Outside Up-to-7   69 56 0.018 1.869 1.10-3.17 0.002 2.499 1.42-4.42 
Within Milan in pre-op assessment 32 95 0.531 0.818 0.44-1.54    
BCLC A    27 86 0.184 1.491 0.82-2.70    
Child A   53 65 0.322 0.758 0.44-1.32    
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Table 3: Univariate and Multivariate analysis of clinical, pathological and gene 
signatures for overall recurrence in patients beyond Milan criteria (n=132) 
  
    Overall Recurrence, events n=45 
   
  
 Patients 
 
Univariate analysis 
 
 
Multivariate analysis 
 
Gene expression signatures Pos Rest pval HR 95% CI pval HR 95% CI 
VI signature [22]  29 103 0.008 2.262 1.22-4.21    
G3 signature [19]  40 92 0.038 1.861 1.02-3.39    
Proliferation [20]  39 93 0.004 2.297 1.28-4.14    
CK19  human [21]  53 79 <0.001 3.031 1.66-5.54 0.001 2.905 1.59-5.32 
CK19 rat [28]  56 76 0.001 2.676 1.46-4.90    
MET signature [18]  34 98 0.181 1.520 0.82-2.83    
Hepatoblastoma_C2 [26]  6 126 0.702 1.318 0.32-5.47    
CTNNB1 [20]  30 102 0.986 0.994 0.48-2.07    
EpCAM 
 
[25]  26 106 0.461 1.301 0.64-2.63    
Cholangiocarcinoma [29]  44 88 0.036 1.855 1.03-3.34    
Recurrence [24]  41 91 0.366 1.323 0.72-2.44    
Cluster A [16]  45 87 0.046 1.802 1.00-3.25    
TGFb [23]  38 94 0.917 1.035 0.54-1.97    
S1 [13]  42 90 0.529 1.215 0.66-2.24    
S2 [13]  15 117 0.132 1.842 0.82-4.14    
S3 [13]  47 85 0.012 0.408 0.20-0.85    
            
IHC           
CK19   6 126 0.321 1.610 0.38-6.85    
EpCAM   20 112 0.416 0.702 0.30-1.66    
bcatenin   27 105 0.381 1.353 0.68-2.68    
RPS6   75 57 0.025 2.024 1.07-3.82    
            
Clinical Variables           
Male gender   105 27 0.558 0.797 0.37-1.71    
Age (>60)   39 93 0.782 1.095 0.57-2.09    
Etiology  HCV 94 38 0.254 1.499 0.74-3.03    
  HBV 19 113 0.204 0.521 0.19-1.46    
  Alcohol 24 108 0.679 1.170 0.56-2.42    
Single tumor >5cm   6 126 0.016 3.306 1.17-9.34 0.023 3.374 1.18-9.63 
2-3 tumors, largest >3cm 51 81 0.168 0.644 0.34-1.21    
No of tumors (>3)   75 57 0.580 1.183 0.65-2.15    
AFP (>200mg/dL)   23 109 0.003 2.579 1.35-4.93    
MiVI   112 20 0.181 1.982 0.71-5.54    
Satellites   24 108 <0.001 3.069 1.65-5.72 <0.001 2.978 1.60-5.55 
Differentiation (Poor)  65 67 0.271 1.388 0.77-2.50    
Outside Up-to-7   69 56 0.241 1.444 0.78-2.67    
Within Milan in pre-op assessment 32 95 0.382 0.710 0.33-1.53    
BCLC A   27 86 0.962 1.018 0.48-2.15    
Child A   53 65 0.587 1.187 0.64-2.12    
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Table 4: Univariate and Multivariate analysis of CK19/S2 score for overall survival in 
patients beyond Milan (n=132) 
 
 
      Overall Survival, events n=64  
        
Univariate analysis 
 
Multivariate analysis 
 
Gene expression Signatures 
Patients 
Pos Rest pval HR 95% CI Pval HR 95% CI 
                    
CK19 [21] and/or S2 pos [13]   58 74 0.030 1.17 1.04-2.79 0.036 1.719 1.034-2.85 
            
IHC           
CK19   6 126 0.571 1.396 0.44-4.46    
EpCAM   20 112 0.096 0.497 0.21-1.15    
bcatenin   27 105 0.334 1.329 0.74-2.37    
RPS6   75 57 0.173 1.414 0.86-2.33    
            
Clinical Variables           
Male gender   105 27 0.441 0.775 0.40-1.49    
Age (>60)   39 93 0.031 1.730 1.04-2.87    
Etiology  HCV 94 38 0.168 1.512 0.84-2.74    
  HBV 19 113 0.381 0.718 0.34-1.51    
  Alcohol 24 108 0.363 1.316 0.73-2.39    
Single tumor >5cm   6 126 <0.001 4.289 1.83-10.07 <0.001 5.510 2.26-13.45 
Two-Three tumors, larger >3cm 51 81 0.118 0.659 0.39-1.12    
No of tumors (>3)   75 57 0.675 1.112 0.68-1.83    
AFP (>200mg/dL)   23 109 0.087 1.650 0.92-2.95    
MiVI   112 20 0.051 2.631 0.96-7.24    
Satellites   24 108 0.056 1.724 0.98-3.04    
Differentiation (Poor)  65 67 0.183 1.398 0.85-2.30    
Outside Up-to-7   69 56 0.018 1.869 1.10-3.17 0.007 2.113 1.23-3.64 
Within Milan in pre-op assessment 32 95 0.531 0.818 0.44-1.54    
BCLC A    27 86 0.184 1.491 0.82-2.70    
Child A   53 65 0.322 0.758 0.44-1.32    
            
 
 
 
5 
 
 
Table 5: Univariate and Multivariate analysis of CK19/S2 score for overall recurrence 
in patients beyond Milan (n=132) 
 
 
    Overall Recurrence, events n=45 
    
Univariate analysis 
 
Multivariate analysis 
Gene expression Signatures 
Patients 
Pos Rest pval HR 95% CI pval HR 95% CI 
          
CK19 [21] and/or S2 pos [13]  58 74 <0.001 3.192 1.67-5.60 <0.001 3.162 1.70-5.89 
          
IHC          
CK19  6 126 0.321 1.610 0.38-6.85    
EpCAM  20 112 0.416 0.702 0.30-1.66    
bcatenin  27 105 0.381 1.353 0.68-2.68    
RPS6  75 57 0.025 2.024 1.07-3.82    
          
Clinical Variables          
Male gender  105 27 0.558 0.797 0.37-1.71    
Age (>60)  39 93 0.782 1.095 0.57-2.09    
Etiology HCV 94 38 0.254 1.499 0.74-3.03    
 HBV 19 113 0.204 0.521 0.19-1.46    
 Alcohol 24 108 0.679 1.170 0.56-2.42    
Single tumor >5cm  6 126 0.016 3.306 1.17-9.34 0.019 3.520 1.23-10.06 
Two-Three tumors, larger >3cm 51 81 0.168 0.644 0.34-1.21    
No of tumors (>3)  75 57 0.580 1.183 0.65-2.15    
AFP (>200mg/dL)  23 109 0.003 2.579 1.35-4.93    
MiVI  112 20 0.181 1.982 0.71-5.54    
Satellites  24 108 <0.001 3.069 1.65-5.72 <0.001 3.078 1.65-5.74 
Differentiation (Poor)  65 67 0.271 1.388 0.77-2.50    
Outside Up-to-7  69 56 0.241 1.444 0.78-2.67    
Within Milan in pre-op assessment 32 95 0.382 0.710 0.33-1.53    
BCLC A  27 86 0.962 1.018 0.48-2.15    
Child A  53 65 0.587 1.187 0.64-2.12    
          
Fig. 1
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